Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Novo Nordisk has received State Food and Drug Administration (SFDA) approval for Victoza to treat type2 diabetes.
Subscribe to our email newsletter
Victoza works by stimulating the release of insulin from the pancreatic beta cells only when blood sugar levels are high.
Victoza is the brand name for liraglutide, the first once-daily human Glucagon- Like Peptide-1 (GLP-1) analogue approved in China, developed for the treatment of type 2 diabetes in adults.
Novo Nordisk executive vice president and chief science officer Mads Krogsgaard Thomsen said the Chinese approval of Victoza represents an exciting opportunity to further advance therapy in people with type 2 diabetes in China.
"Diabetes is a rapidly growing disease in China, and Victoza offers a unique treatment option by effectively reducing HbA1c and weight with a low risk of hypoglycaemia in people with type 2 diabetes inadequately controlled by oral anti-diabetic agents," Thomsen said.